Connecticut’s Medicaid program relies on average wholesale prices reported by drug manufacturers to First DataBank, which the state uses to set reimbursement rates for pharmacies. McKesson allegedly reported inflated prices of more than 400 name-brand drugs, including Lipitor, Celebrex and Neurontin, by more than 25 percent of their usual wholesale costs, according to the report.
The settlement calls for the company to reimburse $9 million to Connecticut’s Medicaid program and $3 million to ConnPace, a state program that provides drug coverage for senior citizens, according to the report.
Read The Day news report about McKesson’s settlement.
Read other coverage about drug pricing:
– Drug Maker Sandoz Settles Drug Pricing Allegations, Agrees to Pay $1.6M to Idaho
– Pharmaceutical Company Teva Settles Drug-Pricing Lawsuits
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
